Novo Nordisk (LLYcasitsucasino.US) fell more than 2% to 121casitsucasino.29 dollars. on the news frontcasitsucasinoAmgen's mid-term trial of a new weight-loss drug receives positive data. If the drug is approved, it will compete with Novo NordiskcasitsucasinoWegovy and Lilly's Zepbound compete.
Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.
